COPD Drugs Linked To Increased Cardiovascular Health Risks: Study
Some COPD treatments can significantly increase the risk of severe heart problems after just one month of treatment, according to the findings of a new study.
Some COPD treatments can significantly increase the risk of severe heart problems after just one month of treatment, according to the findings of a new study.
A new study raises concerns that Respimat, as soft mist inhaler, may carry more heart risk than Spiriva.
The FDA has announced a recall of more than 15 million Spiriva Handihaler Capsules due to foreign particles.
The findings of a new study resurrects concerns that some long-acting inhalers used to treat chronic pulmonary obstructive disease (COPD), such as Spiriva and Serevent, could increase the risk of…
Boehringer Ingleheim’s relatively new anticoagulant Pradaxa has hit blockbuster status, even amid hundreds of deaths and other serious injuries caused by bleeding problems experienced by users of the medication.
Potential side effects of Spiriva mist inhalers, which are not yet approved for sale in the United States, could increase the risk of death by more than 50%, according to…
The side effects of Spiriva, Combivent, Atrovent and other inhalers used to treat breathing difficulties could be linked to urinary problems in men, according to the findings of a recent…
The FDA has concluded their investigation into potential side effects of Spiriva HandiHaler, and the agency indicates that they did not find a link between the chronic pulmonary obstructive disease…
Yesterday the FDA issued an update to an early communication originally released in March 2008 regarding Spiriva Handihaler side effects. After reviewing preliminary data from a four year study, the…
According to research published today in the Journal of the American Medical Association, those using the Spiriva Handihaler or an older generic inhaler called ipratropium, could face an increased risk…